The general director of Medecins Sans Frontieres Christopher Stokes and the President of MSF Belgium Meinie Nicolai visit Elwa hospital in Monrovia September 7, 2014. (AFP/Dominique Faget)
Your feedback is important to us!
We invite all our readers to share with us their views and comments about this article.
Disclaimer: Comments submitted by third parties on this site are the sole responsibility of the individual(s) whose content is submitted. The Daily Star accepts no responsibility for the content of comment(s), including, without limitation, any error, omission or inaccuracy therein. Please note that your email address will NOT appear on the site.
Alert: If you are facing problems with posting comments, please note that you must verify your email with Disqus prior to posting a comment. follow this link to make sure your account meets the requirements. (http://bit.ly/vDisqus)
The first volunteer in a fast-tracked British safety trial of an experimental Ebola vaccine made by GlaxoSmithKline received the injection Wednesday, trial organizers said.The candidate Ebola vaccine, which GSK co-developed with the United States National Institutes of Health, has also been given to 10 volunteers taking part in a separate trial in the United States, and so far there were no signs of any serious adverse reactions, doctors said.Study data from an animal trial of an Ebola vaccine similar to this GSK one showed that it was effective for at least five weeks in lab monkeys but required boosting with an additional vaccine to extend its protection to 10 months.
FOLLOW THIS ARTICLE